The costs of treating acute heart failure: An economic analysis of the SURVIVE trial

Journal of Medical Economics

Volumn 11, Issue 3, 2008, Pages 415-429

  de Lissovoy, Gregory ^a   Fraeman, Kathy ^a   Salon, Jeff ^b   Woodward, Tatia Chay ^a   Sterz, Raimund ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Acute heart failure; Dobutamine; Economic evaluation; Inotropes; Levosimendan

Indexed keywords

DOBUTAMINE; LEVOSIMENDAN;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; FRANCE; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LENGTH OF STAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT CARE; SURVIVAL; TREATMENT OUTCOME; UNITED KINGDOM;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; CARDIOTONIC AGENTS; COST-BENEFIT ANALYSIS; DOBUTAMINE; FEMALE; HEALTH EXPENDITURES; HEART FAILURE; HUMANS; HYDRAZONES; LENGTH OF STAY; MALE; MIDDLE AGED; PATIENT ADMISSION; PYRIDAZINES;

EID: 55049107613     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990802291679     Document Type: Article

References (27)

1. Cleland JG, Swedberg K, Follath F et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. European Heart Journal 2003; 24(5): 442-463.
2. Bayram M, De Luca L, Massie MB, Gheorghiade M. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. American Journal of Cardiology 2005; 96: 47G-58G.
3. Shin DD, Brandimarte F, De Luca L et al. Review of current and investigational pharmacologic agents for acute heart failure syndromes. American journal of Cardiology 2007; 99: 4A-23A.
4. Mebazaa A, Nieminen MS, Packer M et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. Journal of the American Medical Association 2007; 297: 1883-1891.
5. Abbott L. 2006 Update SIMDEX Summary of Product Characteristics (SmPC) 2007.
6. Felker GM, Leimberger JD, Califf RM et al. Risk stratification after hospitalization for decompensated heart failure. Journal of Cardiac Failure 2004; 10: 460-466.
7. Fonarow GC, Adams KF, Jr., Abraham WT et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. Journal of the American Medical Association 2005; 293: 572-580.
8. Gheorghiade M, Abraham WT, Albert NM et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. Journal of the American Medical Association 2006; 296: 2217-2226.
9. Lee TT, Chen J, Cohen DJ, Tsao L. The association between blood pressure and mortality in patients with heart failure. American Heart Journal 2006; 151: 76-83.
10. Brophy JM, Dagenais GR, McSherry F, Williford W, Yusuf S. A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. American Journal of Medicine 2004; 116: 300-304.
11. Ingenix. DRG Expert 2005: A comprehensive reference to the DRG classification system Salt Lake (Utah): Ingenix; 2005.
12. Agence Technique de l'information sur l'hospitalisation. Tarifs des prestations d'hospitalisation, 29/03/2004. Available at: http://www.atih.sante.fr/?id=000000000000. Accessed 1 October 2007.
13. Fallpauschalen-Katalog Available at: http://www.gesundheitspolitik.com/ 03_krankenhaus/fallpauschalen/gdrg2005/ DRG2005-Fallpauschalen-Zusatzentgelte-20040915.pdf. Accessed 1 October 2007.
14. UK Department of Health. National Tariff 2005-2006. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH_4133221. Accessed 1 October 2007.
15. Organization for Economic Co-operation and Development. Purchasing Power Parities and Real Expenditures: 2002 Benchmark Year. Accessed 1 October 2007
16. Efron B TR. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Statistics & Science 1986; 1: 54-75.
17. Manning WG BA, Mullahy J. Modeling costs with generalized gamma regression [working paper]. Available at: http://www.src.uchicago.edu/ prc/pdfs/mannin02.pdf. Accessed 1 October 2007.
18. Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. European Heart Journal 1999; 20: 136-139.
19. Cleland JGF, Takala A, Apajasalo M, Zethraeus N, Kobelt G. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial. European Journal of Heart Failure 2003; 5: 101-108.
20. Campbell MK, Torgerson DJ. Bootstrapping: estimating confidence intervals for cost-effectiveness ratios. Quarterly Journal of Medicine 1999; 92: 177-182.
21. O'Brien BJ, Briggs AH. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Statistical Methods and Medical Research 2002; 11: 455-468.
22. Gheorghiade M, Zannad F. Modern management of acute heart failure syndromes. European Heart Journal 2005; 7(Suppl.): B3-B7.
23. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. British Medical Journal 2004; 329: 224-227.
24. Cook JR, Drummond M, Glick H, Heyse JF. Assessing the appropriateness of combining economic data from multinational clinical trials. Statistics & Medicine 2003; 22: 1955-1976.
25. Gafni A. Proper preference-based outcome measures in economic evaluations of pharmaceutical interventions. Medical Care 1996; 34(12 Suppl.): DS48-58.
26. Packer M, Coats AJ, Fowler M et al. Effect of Carvedifol on Survival in Severe chronic heart failure. New England Journal of Medicine 2001; 344: 1651-1658.
27. Follath F, Cleland JGF, Just H et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196-202.